FDA Approves myBETAapp and BETACONNECT Navigator

A new mobile and cloud-based health technology offered by Bayer has been approved by the United States Food and Drug Administration (FDA) for individuals taking Betaseron for relapsing-remitting MS. On May 30, 2017, Bayer announced the approval of myBETAapp™ and the BETACONNECT Navigator™.

With this software, in conjunction with Bluetooth technology, individuals using the electronic BETACONNECT autoinjector to administer Betaseron® (interferon beta-1b) are able to connect their mobile device or computer to record and store their injection information. Through this technology, participants are then able to share their injection data with their healthcare team – allowing them to see an exact record of when a patient has taken his or her medication.

Individuals who administer their Betaseron through a different injection method and do not use the electronic BETACONNECT autoinjector are also able to participate in this program. With myBETAapp on their mobile device or computer, they may manually enter the information about their injections and share this data with their healthcare team.

The need for this technology was identified through patient feedback and will be available for free download at the Apple app store, Google Play app store, or Betaseron.com in mid-July. According to Bayer, patients enrolled in BETAPLUS®, Bayer’s comprehensive patient support program, can speak directly to a BETA Nurse, who is specially trained in MS.

For more information on Betaseron and this technology, please visit the following links:

For full prescribing information, please visit: http://labeling.bayerhealthcare.com/html/products/pi/Betaseron_PI.pdf

For BETACONNECT instructions for use, please visit: http://labeling.bayerhealthcare.com/html/products/Betaconnect_IFU.pdf

For myBETAapp instructions for use, please visit: http://labeling.bayerhealthcare.com/html/products/mybetaapp_IFU.pdf

To contact BetaPlus for general information on Betaseron, please call (800) 788-1467 or visit www.betaseron.com. Please note that information on myBETAapp and BETACONNECT Navigator may not be available at this number until this technology can be downloaded in mid-July.

For additional information on MS or to speak with a trained Client Services Specialist, please call MSAA’s Helpline at (800) 532-7667, extension 154. Questions to MSAA’s Client Services department may also be emailed to MSquestions@mymsaa.org.

Written by Susan Courtney, MSAA Senior Writer